Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-2
pubmed:dateCreated
2002-5-1
pubmed:abstractText
Previously, we have reported the development of a new quantitative-competitive polymerase chain reaction (qc-PCR) method to evaluate interferon-beta (IFNbeta) bioavailability in multiple sclerosis (MS) patients, by measuring mRNA of mixovirus resistance protein A (MxA). Here we show that our assay is also able to assess IFNalpha bioavailability in hepatitis C virus (HCV) patients treated with different IFNalpha regimens. Indeed, our method was able to detect a slight constitutive expression of MxA mRNA in untreated HCV patients (median=70 fgMxA/pgGAPDH) and a significant induction 12 h after the first IFNalpha administration (median=750 fgMxA/pgGAPDH).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0022-1759
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
262
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
187-90
pubmed:dateRevised
2005-5-27
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Evaluation of IFNalpha bioavailability by MxA mRNA in HCV patients.
pubmed:affiliation
Centro Sclerosi Multipla and Laboratorio di Neurobiologia Clinica, Divisione Universitaria di Neurologia, Azienda Ospedaliera S. Luigi, Università di Torino, Regione Gonzole 10, 10043 Orbassano, Italy. NSGLB@TIN.IT
pubmed:publicationType
Journal Article